Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the ...

LAWRENCEVILLE, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA ... by the rise in viral nucleocapsid antigen ...

The core of the virus is the nucleocapsid, a structure that is made of the viral genome along with C proteins. The nucleocapsid is surrounded by a membrane called the viral envelope, a lipid ...

Generally, testing for prior infections involves looking for antibodies that bind to viral proteins, particularly those that target SARS-CoV-2’s nucleocapsid (N) protein (anti-N antibodies), as the ...

Using a combination of protein biochemistry and cell biology techniques, the researchers found that one part of the cleaved protein, a nucleocapsid fragment that has been reported to bind nucleic ...